2,2,4-Trimethylpentan-1-amine | 44798-19-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,2,4-Trimethylpentan-1-amine
• CAS: 44798-19-8
• 化学式: C₈H₁₉N
• mdl: MFCD06213351
• 分子量: 129.24
• InChiKey: AKYZNGLLWXGHMQ-UHFFFAOYSA-N

物化性质

• 沸点：
  150.1±8.0 °C(Predicted)
• 密度：
  0.784±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] METHOD FOR PRODUCING AN OPTICALLY ACTIVE NITRO COMPOUND<br/>[FR] PROCEDE DE PRODUCTION D'UN COMPOSE NITRO OPTIQUEMENT ACTIF
  申请人：CARREIRA ERICK M

  公开号：WO2004103951A1

  公开（公告）日：2004-12-02

  An optically active nitro compound having two hydrogen atoms on its α-cabon atom and having β-asymmetric carbon atom can be produced by making α, β-unsaturated nitroolefin having a hydrogen atom on its α-cabon atom react with at least two organosilicon compounds having at lest one silicon-hydrogen bond in the molecule in the presence of an asymmetric copper complex, or react with an organosilicon compound having at least one silicon-hydrogen bond in the molecule in the presence of an asymmetric copper complex and water.

  具有两个氢原子的α-碳原子和β-手性碳原子的光学活性硝基化合物可以通过使具有α-碳原子上的氢原子的α，β-不饱和硝基烯烃与至少两个分子中至少有一个硅-氢键的有机硅化合物在存在不对称铜配合物的情况下反应，或者在存在不对称铜配合物和水的情况下，使具有至少一个硅-氢键的有机硅化合物与α-碳原子上的氢原子反应来制备。
• AMINOTHIAZOLE DERIVATIVE
  申请人：Yabuuchi Tetsuya

  公开号：US20120220767A1

  公开（公告）日：2012-08-30

  A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase γ inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

  由式（1）表示的化合物或其药学上可接受的盐，具有PI3激酶γ抑制作用，可用作关节风湿、克罗恩病、肠易激综合征、干燥综合征、多发性硬化、系统性红斑狼疮、哮喘、特应性皮炎、动脉硬化、器官移植排斥、癌症、视网膜病变、牛皮癣、关节病变、年龄相关性黄斑变性、2型糖尿病、胰岛素抵抗、肥胖、非酒精性脂肪肝病（NAFLD）、非酒精性脂肪性肝炎（NASH）、高脂血症等疾病的预防或治疗剂。
• Cephalosporin intermediates
  申请人：——

  公开号：US20030153748A1

  公开（公告）日：2003-08-14

  A process and intermediates in the production of cefotiam (hexetil).

  头孢替安（己醇）的生产过程和中间体。
• [EN] PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR
  申请人：MERCK & CO., INC.

  公开号：WO1992018132A1

  公开（公告）日：1992-10-29

  (EN) Disclosed is a new treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5$g(a)-reductase inhibitor, e.g. a 17$g(b)-substituted non-azasteroid, 17$g(b)-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, e.g. finsteride, in combination with an aromatase inhibitor, i.e., fadrazole, being 4-(5,6,7,8-tetra-hydroimidazo-[1,5-$g(a)]pyridin-5-yl)benzonitrile. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.(FR) On décrit un nouveau traitement destiné aux hommes souffrant d'hyperplasie prostatique bénigne (HPB), et qui comprend une thérapie d'association composée d'un inhibiteur de 5$g(a)-réductase, par exemple un dérivé d'acide benzoylaminophénoxybutanoïque, 17$g(b)-substitué non azastéroïde, 17$g(b)-acyl-3-carboxy-androst-3,5-diène, un dérivé de cinnamoylamide ou de benz(thio)amide fusionné, des thioéthers ou 1,2-diéthers aromatiques, des acides alcanoïques aromatiques d'ortho acylaminophénoxy, des acides alcanoïques d'ortho thioalkylacylamino-phénoxy, des sels et des esters pharmaceutiquement acceptables de ces éléments, par exemple de la finastéride, en association avec un inhibiteur d'aromatase, c'est-à-dire du fadrazole, étant composé de 4-(5,6,7,8-tétrahydro-imidazo-[1,5-$g(a)]pyridin-5-yle) benzonitrile. L'association constitue une thérapie au niveau moléculaire dirigée contre la cause sous-jacente de la maladie tout en produisant un soulagement symptomatique. Des compositions pharmaceutiques utilisées pour ce traitement sont aussi décrites.

  该专利公开了一种新的治疗良性前列腺增生（BPH）的方法，涉及使用5α-还原酶抑制剂的联合治疗，例如17β-取代的非阿扎斯特罗伊德类、17β-酰基-3-羧基-雄烯-3,5-二烯、苯甲酰氨基苯氧丁酸衍生物、融合苯（硫）酰胺或肉桂酰胺衍生物、芳香族1,2-二醚或硫醚、芳香族正交酰胺基苯氧基烷酸、正交硫烷基酰胺基苯氧基烷酸，以及其药学上可接受的盐和酯，例如非那雄胺，与芳香化酶抑制剂，即4-（5,6,7,8-四氢咪唑[1,5-a]吡啶-5-基）苯甲腈的联合使用。该联合疗法在分子水平上治疗疾病的根本原因，并提供症状缓解。还公开了用于治疗的药物组合。
• Immunomodulating Heterocyclic Compounds
  申请人：Matthews Ian Richard

  公开号：US20090312334A1

  公开（公告）日：2009-12-17

  Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R 1 and R 3 independently represent H; F; Cl; Br; —NO 2 ; —CN; C 1 -C 6 alkyl optionally substituted by F or Cl; or C 1 -C 6 alkoxy optionally substituted by F; R 4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR 6 R 7 , —NR 7 C(═O)R 6 , —NR 7 C(═O)OR 6 , —NHC(═O)NR 7 R 6 or —NHC(═S)NR 7 R 6 wherein R 6 represents H, or a radical of formula -(Alk) m -Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C 1 -C 12 alkylene, or C 2 -C 12 alkenylene, or C 2 -C 12 alkynylene radical or a divalent C 3 -C 12 carbocyclic radical, any of which radicals may contain one or more —O—, —S— or —N(R 8 )— links wherein R 8 represents H or C 1 -C 4 alkyl, C 3 -C 4 alkenyl, C 3 -C 4 alkynyl, or C 3 -C 6 cycloalkyl, and Q represents H; —NR 9 R 10 wherein R 9 and R 10 independently represents H; C 1 -C 4 alkyl; C 3 -C 4 alkenyl; C 3 -C 4 alkynyl; C 3 -C 6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R 9 and R 10 form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and R 7 represents H or C 1 -C 6 alkyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula -(Z) n -(Alk)- or -(Alk)-(Z) n - wherein Z represents —O—, —S— or —NH—, Alk is as defined in relation to R 6 and n is 0 or 1.

  公式（I）的化合物是CD80的抑制剂，可用于免疫调节治疗：其中，R1和R3分别表示H; F; Cl; Br; -NO2; -CN; C1-C6烷基，所述烷基可选地被F或Cl取代; 或C1-C6烷氧基，所述烷氧基可选地被F取代; R4表示羧酸基(-COOH)或其酯，或-C（═O）NR6R7，-NR7C（═O）R6，-NR7C（═O）OR6，-NHC（═O）NR7R6或-NHC（═S）NR7R6，其中R6表示H，或式-(Alk)m-Q的基团，其中m为0或1，Alk是可选地取代的二价直链或支链C1-C12烷基，或C2-C12烯基，或C2-C12炔基基团或二价C3-C12环烷基基团，其中任何一个基团可以含有一个或多个-O-，-S-或-N（R8）-键，其中R8表示H或C1-C4烷基，C3-C4烯基，C3-C4炔基或C3-C6环烷基，而Q表示H; -NR9R10，其中R9和R10独立地表示H; C1-C4烷基; C3-C4烯基; C3-C4炔基; C3-C6环烷基; 酯基; 可选地取代的环烷基或杂环基; 或者R9和R10与它们所连接的氮一起形成一个环，该环是可选地取代的; 而R7表示H或C1-C6烷基; 或者当R6和R7与它们所连接的原子或原子一起形成一个可选地取代的含5、6或7个环原子的单环杂环时; 而X表示键或式-(Z)n-(Alk)-或-(Alk)-(Z)n-的二价基团，其中Z表示-O-，-S-或-NH-，Alk如在R6中所定义，n为0或1。